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Abstract
Background: Ph-negative myeloproliferative neoplasms (MPNs) are clonal disorders that include primary myelofibrosis
(PMF), polycythemia vera (PV) and essential thrombocythemia (ET). Although the pathogenesis of MPNs is still incompletely
understood, an involvement of the megakaryocyte lineage is a distinctive feature.
Methodology/Principal Findings: We analyzed the in vitro megakaryocyte differentiation and proplatelet formation in 30
PMF, 8 ET, 8 PV patients, and 17 healthy controls (CTRL). Megakaryocytes were differentiated from peripheral blood CD34
+
or CD45
+ cells in the presence of thrombopoietin. Megakaryocyte output was higher in MPN patients than in CTRL with no
correlation with the JAK2 V617F mutation. PMF-derived megakaryocytes displayed nuclei with a bulbous appearance, were
smaller than ET- or PV-derived megakaryocytes and formed proplatelets that presented several structural alterations. In
contrast, ET- and PV-derived megakaryocytes produced more proplatelets with a striking increase in bifurcations and tips
compared to both control and PMF. Proplatelets formation was correlated with platelet counts in patient peripheral blood.
Patients with pre-fibrotic PMF had a pattern of megakaryocyte proliferation and proplatelet formation that was similar to
that of fibrotic PMF and different from that of ET.
Conclusions/Significance: In conclusion, MPNs are associated with high megakaryocyte proliferative potential. Profound
differences in megakaryocyte morphology and proplatelet formation distinguish PMF, both fibrotic and prefibrotic, from ET
and PV.
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Introduction
Megakaryocytes and platelets, which are their progeny, are
highly specialized cells that participate in hemostatic and inflam-
matory functions. Since each platelet lives only about 10 days, the
platelet supply is continually renewed by production of new
platelets from the maturation of megakaryocytes [1]. The most
recognized model of platelet formation provides that it occurs in
the bone marrow environment where megakaryocytes extend long
filaments, called proplatelets, that protrude through the vascular
endothelium into the sinusoid lumen, where the platelets are
released [2–6]. Physiological evidence of proplatelet formation has
been demonstrated by electron microscopy analysis [7] and, more
recently, proplatelet formation and platelet release has been shown
by multiphoton intravital microscopy in intact bone marrow from
mice [8]. However, many aspects regarding the mechanisms
underlying proplatelet extension and platelet release remain
unsolved, especially in humans [9]. Consequently, insight into
the pathogenesis of megakaryocyte related diseases as well as
treatment options are missing. Among the diseases, myloprolifera-
tive neoplasms (MPNs), which include polycythemia vera (PV),
essential thrombocythemia (ET) and primary myelofibrosis (PMF),
represent one of the most severe clinical picture that is still
incurable. In PV, megakaryocytes are increased in number and
display characteristic morphological abnormalities, such as
hyperlobated nuclei. They are distinguishable from those in ET,
which typically tend to form loose clusters or to lie close the bone
marrow trabeculae and often show a significant degree of
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21015pleomorphism with variable sizes. PMF is characterized by
important hyperplasia and atypia of megakaryocytes, whose nuclei
appear hypolobated and cloud-like [10],[11]. Available informa-
tion on mutations of genes encoding tyrosine kinases and their
pathways do not explain entirely the molecular pathogenesis of
MPNs and this lack of information contributes to the slow
development of effective treatments. This justifies the continuous
search for new cellular and molecular aberrations that specifically
characterize these disorders and could become targets of new
therapies. Previous studies demonstrated that megakaryocyte
hyperplasia in PMF is, most likely, the consequence of both the
increased ability of CD34
+ progenitors to generate megakaryo-
cytes and the decreased rate of megakaryocyte apoptosis, as
suggested by their over-expression of the antiapoptotic protein bcl-
xl [12]. Moreover, aberrant proplatelet formation has been shown
in bone marrow from patients with MPNs [13]. Overall, these data
suggest that abnormal megakaryopoiesis is a key feature of MPNs
in general and of PMF primarily. However, it is unknown whether
the pathological mechanisms underlying MPNs are caused by
intrinsic defects of megakaryocyte function or by abnormalities of
the bone marrow microenvironment, which regulates megakar-
yocyte formation and function.
In this study we investigated the in vitro pattern of differentiation of
megakaryocytes from circulating hematopoietic progenitors ob-
tained from patients with different MPNs and the capacityof these in
vitro-differentiated megakaryocytes to form and extend proplatelets.
Results
MPNs display increased numbers of differentiating
megakaryocytes
Megakaryocytes were derived from peripheral blood hematopoi-
etic progenitor cells of 30 patients with PMF (13 pre-fibrotic and 17
fibrotic), 8 patients with ET, 8 patients with PV and 17 CTRL.
CD45
+ cell-initiated megakaryocyte cultures were performed in 13
patientswithPMF(10pre-fibroticand 5fibrotic),8patientswithET,
8 patients with PV and 7 CTRL (Figure 1A). The median output of
CD41
+ megakaryocytes at day 14 was 2.2% (range: 1.02–3.37) in
CTRL, 8.61% in pre-fibrotic PMF (range: 3.6–30.86), 8.51% in
fibrotic PMF (range: 2.33–56.71), 8.18% in ET (range: 1.7–19.8),
7.36% in PV (range: 2.8–24.9). Differences between MPN patients
and CTRL were statistically significant (p,0.01), while differences
among the 4 types of MPN were not statistically significant.
The in vitro production of megakaryocytes from CD34
+ cells
obtained from peripheral blood was studied in 15 patients with
PMF (3 pre-fibrotic and 12 fibrotic) and 10 CTRL (Figure 1B).
Immunomorphological analysis revealed that the median output
of CD41
+ cells with megakaryocyte morphology at day 14 was
71.14% (range: 30.1–193.9%) in CTRL, 99.75% (range: 39.8–
303.8%) in pre-fibrotic PMF, 88.93% (range: 23.3–689.4%) in
PMF. Although PMF progenitors displayed a trend towards
increased capacity to generate megakaryocytes, the difference was
not statistically significant among the three groups. This may be
due to the higher variability in cell maturity and differentiation
potential of mobilized CD34
+ cells in CTRL [14–16].
Finally, no statistically significant differences in megakaryocyte
output were observed between JAK2 V617F and wild type JAK2
patients (not shown).
Megakaryocytes derived from pre-fibrotic and fibrotic
PMF show peculiar characteristics compared to other
MPNs and CTRL
Analysis of megakaryocyte morphology according to standard
criteria [17] revealed significant differences in the maturation
profile of PMF compared to PV, ET and CTRL, indicating a
peculiar defect of megakaryocyte development in PMF compared
to other MPNs (Figure 2A). Consistently, a lower percentage of
PMF derived megakaryocytes was polyploid (.8N) compared to
CTRL (Figure 2B). Moreover, the majority of PMF derived
megakaryocytes presented bulbous nuclei, while almost no
megakaryocytes from CTRL did (Figure 2C). Finally, diameter
of megakaryocytes was measured at the end of the culture and
prior to proplatelet formation. Megakaryocytes from PMF
displayed a decreased diameter than those from ET, PV and
CTRL (Figure 2D). Overall, our data confirm and extend previous
observations [12], demonstrating that, although PMF generated
more megakaryocytes, they were smaller and presented abnormal
morphology of nuclei, compared to the other MPNs and CTRL.
In order to exclude that differences in megakaryocyte morphol-
ogy were dependent on the maturation stage of progenitors derived
Figure 1. Box-and-whisker plots of megakaryocyte output in
suspension cultures. CD45
+ (A) and CD34
+ (B) cells from peripheral
blood were sorted as described in Methods and cultured for 14 days. At
the end of the cultures, the yield of megakaryocyte was calculated as
output of CD41
+ cells with megakaryocyte morphology. CTRL: healthy
controls; PMF: primary myeolofibrosis; ET: essential thrombocytemia; PV
polycytemia vera. *p,0.01.
doi:10.1371/journal.pone.0021015.g001
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PMF derived cultures. Progenitors derived from fibrotic and pre-
fibrotic PMF were maintained in culture for 18 days and
megakaryocyte morphology was analyzed. Results demonstrated
that, even prolonging the culture incubation time, megakaryocytes
derived from PMF remained smaller than CTRL and showed the
same characteristics of immaturity observed when cultures were
performed for shorter period of time (not shown). Overall these data
demonstrate that impaired megakaryocyte development occurs in
PMF, while in other MPN megakaryocytes mature normally.
Proplatelet formation shows distinct abnormalities in the
different MPNs and correlate with the clinical
phenotypes
Studies in liquid culture suspension. In order to explore
whether defects in megakaryocyte development were associated to
altered megakaryocyte function, we investigated the generation of
proplatelets by MPN-derived and CTRL-derived megakaryocytes.
Mature megakaryocytes, at the end of the culture, were reseeded
and proplatelet formation was evaluated after 16 hours. In CTRL
samples, a median of 7.5% (range: 2.6–11%) of megakaryocytes
formed proplatelets, compared to 3.8% (range: 0–5%) of PMF-
derived megakaryocytes, 8.65% (range: 5.5–20%) of ET-derived
megakaryocytes and 9.15% (range: 6–23.9%) of PV-derived
megakaryocytes (p=0.001 for all the comparisons). No differences
were observed between pre-fibrotic (median: 3.3%, range: 0–
12.4%) and fibrotic PMF (median: 4.3%, range: 2.7–8.8%)
(Figure 3A). There was a moderate correlation between the
platelet count in peripheral blood and the in vitro proplatelet
formation of MPN patients (r=0.36; P=,0.05; Figure 3B). This
was particularly evident in PMF: patients with thrombocytopenia
(platelet count lower than 150610
9/L, N=3) had the more severe
defect in proplatelet formation (median 2.7%, range 0–4.7). The
JAK2 V617F mutation did not affect proplatelet formation neither
in any category of MPN (not shown).
Nascent normal platelets form exclusively at the level of the
terminal ends of the proplatelet shafts (i.e. the proplatelet tips) and
the number of platelets that form is a function of the number of
tips and shaft bifurcations [7]. We found that the proplatelets
extended by PMF megakaryocytes presented several alterations
with respect to CTRL. Specifically, proplatelets had a very
variable numbers of bifurcations that frequently did not present
any tips at the terminal end. Consequently, we observed a
significant reduction of tips with respect to CTRL proplatelets,
thus indicating a defect in proplatelet structure (Figure 4A–C). In
contrast, ET- and PV-derived proplatelets displayed a striking
increase in bifurcations and tips compared to both CTRL and
PMF (Figure 4A–C). No other defects in proplatelet structure and
tubulin distribution were observed (Figure 4A).
Studies in cell adhering to adhesive proteins. Experiments
were also performed under conditions in which megakaryocytes
were let to adhere to fibrinogen, an adhesive proteins that positively
regulate proplatelet formation. In CTRL samples, a median of
7.4% (range: 3.2–13.9%) of megakaryocytes formed proplatelets,
compared to 1% (range: 0–12.9%) of PMF-derived megakaryo-
cytes, 8.3% (range: 6.2–26.5%) of ET-derived megakaryocytes and
10.7% (range: 7.1–15.8%) of PV-derived megakaryocytes (p=0.01
for all the comparisons). No differences were observed between pre-
fibrotic (median: 6.35%, range: 0–11.5%) and fibrotic PMF
(Figure 5A). Further, as for suspension cultures, PMF-derived
proplatelets showed a simpler structure as compared to CTRL, ET
and PV (Figure 5B I–II). In contrast, proplatelets extended by ET-
and PV-derived megakaryocytes displayed the same morphology
observed in suspension cultures with an evident increase of shaft
bifurcations and tips with respect to CTRL (Figure 5 III–IV). Taken
together, these data demonstrate that the PMF-derived mega-
karyocytes present intrinsic defect in extending proplatelets that are
independent from substrate regulation.
Discussion
Megakaryocytes are large bone marrow cells that release platelets
into the blood stream by elongating proplatelets [3–6]. Recent
studies pointed to a key role of abnormal megakaryocytopoiesis in
the pathogenesis of MPNs [12],[13], however , little is known about
the latter stage of megakaryocyte development and proplatelet
formation in these diseases. Therefore, we studied megakaryocyte
differentiation and proplatelets formation in vitro, by culturing
progenitor cells from in PMF, ET and PV patients, with the aim of
establishing to what extent the observed abnormalities are
attributable to intrinsic cellular defects [27]. Indeed, we found that
eachMPNcategory displayedpeculiaralterations of megakaryocyte
differentiation and function in vitro, suggesting that, besides the
potential deregulation of bone marrow microenvironment, intrinsic
defects of megakaryocyte function contribute to the pathogenesis of
MPNs. Consistently with a previous report by Ciurea et al [12], we
found that the in vitro megakaryocytopoiesis from progenitor cells
derived from PMF, ET and PV patients was increased compared to
healthy controls, with no statistically significant differences observed
among the types of MPNs. Moreover, in MPNs the capacity of stem
cells to generate more megakaryocytes was not associated with the
presence of the V617F mutation of the JAK2 gene [12]. These data
suggest that other, yet-unknown, genetic mutations may contribute
to altered megakaryopoiesis in MPNs [18–22]. Interestingly, PMF
megakaryocyteswere smaller than thoseofotherMPNorofCTRL:
these findings are in keeping with the well known morphological
alterations of megakaryocytes that can be observed in bone marrow
biopsies, which represent a key element for the diagnosis of the
different types of MPN [23–26,28–30]. Most importantly, our
results could be correlated with recent data by Besancenot et al. that
claimed that malignant megakaryocytes undergo abnormal prolif-
eration by escaping the phisiological mechanisms of cell cycle arrest
and senescence induced by TPO signalling [27].
PMF-derived megakaryocytes showed a defect in proplatelet
formation, at variance with ET- and PV-derived megakaryocytes,
which produced more proplatelets compared to CTRL-derived
megakaryocytes. Moreover, a positive correlation between in vitro
proplatelet formation and the platelet count in MPN patients’
peripheral blood was observed. Moreover, consistently with the
Figure 2. Characteristics of megakaryocyte morphology in MPNs and controls (CTRL). (A) Representative picture of differently shaped
CD41
+ (red) cells of controls (I), pre-fibrotic PMF(II), PMF (III), ET (IV) and PV (V). Nuclei are counterstained with Hoechst 33258 (blue). Scale bars are
15 mm. (B) Ploidy was analyzed as described in Methods. PMF derived megakaryocytes presented lower polyploidy with respect to controls. (C) PMF
derived CD41
+ megakaryocytes (red) displayed bulbous and hypo-segmented nuclei.(blue) (left panel). Scale bar is 15 mm. Means 6 SD of the
percentage of megakaryocytes displaying abnormal nuclei in pre-fibrotic PMF and PMF, as compared to control, are reported in the right panel. (D)
Diameters of MPN derived CD41
+ megakaryocytes (red) were analyzed as shown in the left panel and were performed as described in Methods. Scale
bar is 10 mm. For each MPN category at least 100 megakaryocytes were analyzed, the means 6 SD of diameters is reported in the right panel.
*p,0.05.
doi:10.1371/journal.pone.0021015.g002
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level of the terminal ends of the proplatelet shafts (i.e. the
proplatelet tips) and that the number of platelets that are produced
is a function of the number of tips and shaft bifurcations [6], we
documented that the number of bifurcations was very variable and
tips for each proplatelet-bearing megakaryocyte were significantly
decreased in PMF patients with respect to other MPNs and
controls, while it was significantly increased in ET and PV
patients. Of particular interest, we found that megakaryocytes
from both pre-fibrotic and fully fibrotic PMF produce less
proplatelets than normal. This finding underscores the biological
diversity of prefibrotic PMF and ET, and supports the distinction
Figure 3. MPNs show important differences in megakaryocyte function and PPF. (A) Box-and-whisker plots of proplatelet output,
expressed as percent of total megakaryocytes. (B) Correlation between the platelet count in peripheral blood and the number of proplatelets formed
in culture in MPN patients. *p,0.01.
doi:10.1371/journal.pone.0021015.g003
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on the basis of bone marrow morphology [28–30] but has not
been universally accepted yet [26].
We also studied proplatelet formation from megakaryocytes that
were adhering to fibrinogen, an adhesive protein known to support
proplatelet formation [31],[32]. Consistently with suspension
cultures, a reduction in proplatelet formation was found in
PMF-derived megakaryocytes, whereas an increase was observed
in PV- and ET-derived megakaryocytes. Further, abnormalities in
proplatelets architecture, observed in suspension culture-derived
proplatelets, were also evident in adhesion to fibrinogen. These
data highlighted the presence of intrinsic defect in megakaryocyte
development that resulted to be independent from the culture
environment and characteristic of each MPN category [33–38].
Interestingly, aberrant proplatelet formation was shown in
histological sections of bone marrow from ET and PMF patients
[13]. This observation represents a step forward our understand-
ing of MPN bone marrow composition and suggests that altered
regulation of proplatelet formation occurs in MPN bone marrow.
Furthermore, our data extend these results demonstrating that
MPN derived megakaryocytes present intrinsic defects in extend-
ing proplatelets that are abnormal both in numbers and structure.
Therefore both set of date point to an aberrant regulation of
proplatelet formation in MPN patients. Finally, our results are also
strengthened by the direct correlation that we found between
platelet count and number of proplatelets.
In conclusion, the results of our study provide important new
elements in the understanding of the biology of megakaryocyte and
proplatelet formation in MPN, and open a new perspective into the
understandingofthepathophysiologyofplateletproduction inthese
disorders. It represents the first step towards the understanding of
basic cell biology and regulatory mechanisms of platelet formation
in MPNs. Our results suggest that our experimental model may be
useful for dissecting the pathogenesis of MPN, for identifying lesions
responsible for disease evolution and for testing therapeutic agents
[33–39]. The long-term goal is to utilize the model to elucidate new
clinical options for disease management.
Materials and Methods
Ethics Statement
The policies for collection and use of blood samples were
approved by the Institutional Review Board of the IRCCS
Policlinico S. Matteo Foundation, and all patients gave consent for
the donation of blood samples.
Patients and controls
We studied 46 patients with MPNs (Table 1): 30 with PMF, 8
with ET and 8 with PV. All patients with PMF referred to the
Center for the Study of Myelofibrosis of the IRCCS Policlinico S.
Matteo Foundation in Pavia, Italy, between March 2007 and
December 2009; none of them was receiving any disease-
modifying therapy at the time of their enrollment in the study;
however, patients with PV were all under treatment with
phlebotomy in order to try to maintain their hematocrit below
45% (males) or 42% (females). In PMF, 17 of these patients met
the 2008 WHO criteria for PMF, fibrotic type (fibrotic PMF) [28],
while the remaining patients met the 2001 WHO criteria for
pre-fibrotic PMF (granulopoiesis hyperplasia with predominance
of immature and segmented forms, and high number and
clustering of atypical megakaryocytes) [29] and had no or minimal
grade reticulin fibrosis (EUMNET grading lower than 1) [30]. ET
and PV patients were referred either to the Center for the Study of
Myelofibrosis of the IRCCS Policlinico S. Matteo Foundation in
Pavia or to the Dipartimento di Medicina, Chirurgia e
Odontoiatria, Universita ` degli Studi di Milano, Azienda Ospeda-
liera San Paolo in Milano. Diagnoses were based on the WHO
criteria [28],[29]. A normal, age and sex matched, control
population consisted in 10 healthy volunteers who were subse-
quently treated with granulocyte-colony stimulating factor (G-
CSF) and 7 students or staff members, who had not been treated
with G-CSF (see Table 1 for clinical and epidemiological data of
healthy controls).
Clinical and Laboratory Assessment
At the time of blood withdrawal for this study, the medical
histories of the patients were collected. In all patients, blood
samples were obtained to determine complete blood count and to
examine peripheral blood smear for differential white blood cell
count. Circulating CD34
+ hematopoietic progenitor cells were
counted using a standard methodology [40] The presence of
V617F mutation of JAK2 was determined using the allele specific-
PCR assay on DNA purified from granulocytes, as reported [41]:
samples were considered homozygous when the percentage of the
mutant allele was greater than 50%.
Differentiation of megakaryocytes and megakaryocyte
morphological analysis
CD34
+ or CD45
+ cells from patients’ and controls’ peripheral
blood samples were separated by immunomagnetic bead selection
as previously described [31],[42]. CD45
+ cells were separated
from patients that presented low numbers of peripheral CD34
+
cells (,10/ml) [42]. CD45
+ and CD34
+ cells were then cultured in
Stem Spam medium (Stem Cell Technologies, Vancouver,
Canada) supplemented with 10 ng/ml TPO, IL-6, and IL-11
(PeproTech EC Ltd, London, UK), at 37uC in a 5% CO2 fully-
humidified incubator, for 14 days, as previously described
[31],[42]. At day 14, 150610
3 cells were collected, cytospun on
glass coverslips and stained with a primary antibody against CD41
(goat polyclonal anti-CD41, 1:100, Santa Cruz Biotechnology,
Heidelberg, Germany) to evaluate megakaryocyte output and
maturation. After washing with PBS, cells were incubated with
10 mg/ml of an anti-goat Ig secondary antibody conjugated with
Alexa Fluor 488 (Invitrogen, Milan, Italy) in PBS at room
temperature (RT) for 1 hour. Nuclear counterstaining was
performed with Hoechst 33258 (100 ng/ml in PBS) at RT for
3 minutes. Specimens were mounted in Pro Long Antifade
Reagent (Invitrogen, Milan, Italy). Negative controls were
routinely performed by omitting the primary antibody. Megakar-
yocytes were identified on the basis of CD41 expression, and
assigned to distinct stages of maturation according to standard
morphological criteria [17]. Megakaryocyte output was calculated
as the percentage of CD41
+ cells at day 14, and normalized to the
total number of CD45
+ or CD34
+ cells obtained from peripheral
blood at the beginning of the cell culture. Measurements of
megakaryocyte diameters were performed on acquired images by
Figure 4. Analysis of proplatelet architecture. (A) Representative picture of differently organized proplatelet revealed by alpha tubulin staining
(green) of controls (I), PMF (II–III), ET (IV) and PV (V). Nuclei are counterstained with Hoechst 33258 (blu). Scale bars are 15 mm. (B) Proplatelet
bifurcations (means 6 SD), which were identified upon immunostaining with an antibody against alpha tubulin. (C) Proplatelet tips (means 6 SD),
which were identified as coiled coil formations localized at the end of proplatelet branches. *p,0.05.
doi:10.1371/journal.pone.0021015.g004
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megakaryocytes were analyzed for each sample [42].
Proplatelet formation
Megakaryocyte yield and proplatelets were evaluated as
previously described at the end of the cell culture [31],[42] both
in culture medium and after adhesion of megakaryocytes to
adhesive proteins. For studies in culture medium, large, mature
megakaryocytes were separated from cultured cells at day 14 by
sedimentation on a bovine serum albumin (BSA, Sigma, Milan,
Italy) gradient (3–4%). For each subject, an aliquot of 1610
5 cells
was replated and incubated for additional 16 hours. The
percentage of megakaryocytes extending proplatelets at 16 h was
assessed by phase contrast and immunofluorescence microscopy,
Figure 5. Proplatelet formation by megakaryocytes adhering to fibrinogen. (A) Box-and-whisker plots of proplatelet output, expressed as
percent of total megakaryocytes, *p,0.01. (B) Representative picture of differently organized proplatelet revealed by alpha tubulin staining (green) of
controls (I), PMF (II), ET (III) and PV (IV). Nuclei are counterstained with Hoechst 33258 (blu). Scale bars are 15 mm.
doi:10.1371/journal.pone.0021015.g005
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Deutschland GmbH, Hamburg, Germany) and a 636/1.25
UplanF1 oil-immersion objective. Proplatelet-bearing megakaryo-
cytes were then cytospun on glass coverslips and double-stained
with antibodies against CD41 and a-tubulin (clone DM1A, Sigma,
Milan, Italy). Megakaryocytes forming proplatelets were identified
as large CD41
+ cells extending a-tubulin-positive long filamentous
structures. The percentage of CD41
+ cells bearing proplatelets was
calculated. Evaluation of proplatelets by phase contrast and
immunofluorescent microscopy resulted in superimposable results.
For each specimen, at least 100 megakaryocytes were evaluated.
The number of branching and platelet-like structures on each
proplatelet-bearing megakaryocyte was calculated.
To analyze the formation of proplatelets from megakaryocytes
adhering to adhesive substrates, 12 mm glass coverslips were
coated with 100 mg/ml fibrinogen (FBG) (Sigma, Milan, Italy), for
2 hours at RT and subsequently blocked with 1% BSA for 1 hour
at RT. Cells at day 14 of culture were harvested, plated onto
substrate-coated coverslips in 24-wells plates (1610
5 cells/well),
and allowed to adhere for 16 hours at 37uC and 5% CO2.
Proplatelet formation was evaluated at 16 hours by phase-contrast
microscopy and by fluorescence microscopy, as described above.
Ploidy analysis
At the end of the cell culture, 5610
5 cells derived from PMF
and CTRL peripheral blood were harvested and stained with a
FITC-conjugated antibody against human CD41 (clone HIP8,
BioLegend, California, USA) for 30 minutes on ice at dark. Then,
cells were fixed in PFA 4% for 20 minutes at RT, permeabilized
with 0,1% Tween 20 (Sigma, Milan, Italy) supplemented with
100 mg/ml RNAse (Sigma, Milan, Italy) and stained with 50 mg/ml
Propidium Iodide (PI) (Sigma, Milan, Italy) for 30 minutes on ice at
dark. Ploidy of megakaryocytes was evaluated by flow cytometry
using a BD LSR II flow cytometer (BD Biosciences, San Jose’, CA,
USA) with DiVa 6.1 data acquisition software (BD Biosciences, San
Jose’, CA, USA). A minimum of 20000 events were collected in the
CD41
+ gate. Non-stained samples, FITC-isotype controls and
fluorochrome minus one (FMO) controls were used to set the
correct analytical gating. Off-line data analysis was performed using
FCS Express 3.0 (DeNovo Software, Los Angeles, CA, USA) and
ModFit LT (Verity, Topsham, ME, USA) software packages.
Statistics
Values are expressed as mean 6 SD or median (range), when
appropriate. Analysis by Kruskall-Wallis test was followed by post-
hoc testing using the critical difference of the mean ranks after
Conover (Conover WJ, 1999, Practical nonparametric statistics,
3
rd edition, New York, John Wiley & Sons). A value of p,0.05 was
considered statistically significant. Statistical analysis was carried
out using SigmaStat 3.0 and Medcalc version 11.5 software. All
experiments were independently replicated at least three times,
unless differently specified.
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